Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

USA Penthrox Update & USA Respiratory Update

Aug 9, 2016Cathy WilsonNews

9 August 2016

ASX ANNOUNCEMENTS – USA Penthrox Update & USA Respiratory Update

USA : Penthrox update

Medical Developments International (ASX: MVP) advises it has received a written response to its meeting request by the Food & Drug Administration (FDA) in the United States of America.  On the basis of the FDA’s written response, MVP has a clearer understanding of the steps required and data needed to get Penthrox approved for sale in the USA.

Amongst certain other requirements, MVP will undertake a second Phase III Pivotal Clinical Trial in the USA for ‘Acute Trauma Pain’.  We expect our USA based trial will include an appropriate mix of ethnically diversified patients.

For details relating to the full ASX release please click on the following link ASX Announcement_USA-Penthrox Update

MVP signs Respiratory deal in the United States.

Medical Developments International Limited (ASX: MVP) is delighted to announce that it has agreed a distribution deal with Cardinal Health Inc. for the distribution of its range of ‘Space Chamber’ anti-static Respiratory Devices in the United States of America (USA).

Cardinal Health is a leader in global pharmaceutical sourcing and distribution services. As one of the largest healthcare supply chains in North America, Cardinal Health Inc. is headquartered in Dublin, Ohio. Cardinal Health, Inc. (NYSE: CAH) is a $103 billion health care services company.

For details relating to the full ASX release please click on the following link ASX Announcement_USA-MVP signs respiratory deal in the USA

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter